The one-line summary
Tirzepatide (Zepbound) is approved, available, and produces 20-22% average weight loss. Retatrutide is in Phase 3 trials with 24% Phase 2 data — but it won't be available until 2027 at earliest. For most patients, the right answer right now is tirzepatide.
When Eli Lilly published retatrutide's Phase 2 results in the New England Journal of Medicine in 2023, the number that stood out was 24.2% average body weight loss at 48 weeks. The obesity medicine community took notice — not because the mechanism was entirely new, but because of how much further it pushed the efficacy ceiling that tirzepatide had recently established.
This comparison matters because both drugs come from Eli Lilly, both involve GIP receptor engagement, and both represent the current frontier of GLP-1-adjacent obesity pharmacotherapy. Understanding how they differ — and what that difference actually means for a patient making a treatment decision today — is what this article addresses.
The Mechanism Difference: Two Receptors vs. Three
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both receptors simultaneously, producing effects that exceed what GLP-1 activation alone achieves — explaining why Zepbound outperforms Wegovy in head-to-head efficacy comparisons.
Retatrutide adds a third receptor: glucagon. The glucagon receptor is sometimes described as physiologically opposed to insulin — it normally promotes glucose release from the liver. But at the doses used in retatrutide, glucagon receptor activation appears to do something different: it increases resting energy expenditure and promotes breakdown of fat from adipose tissue directly.
The practical implication is that retatrutide works through three simultaneous pathways: appetite suppression via GLP-1, enhanced insulin response via GIP, and what might be described as elevated metabolic activity via glucagon. Whether this triple-agonism translates cleanly from Phase 2 to Phase 3 at population scale is what the TRIUMPH trials are designed to determine.
Clinical Trial Data: What We Actually Know
| Retatrutide | Tirzepatide (Zepbound) | |
|---|---|---|
| Trial phase | Phase 2 (338 participants) | Phase 3 (2,539 participants) |
| Duration | 48 weeks | 72 weeks |
| Avg weight loss | 24.2% (12mg dose) | 20.9% (15mg dose) |
| ≥20% weight loss | ~45% | ~37% |
| ≥25% weight loss | ~26% | ~27% |
| FDA approved | No | Yes (obesity, 2023) |
| Available now | No | Yes |
| Est. availability | 2027-2028 | Now |
Side Effect Profile: Largely Comparable
Both drugs produce similar side effect patterns: nausea, vomiting, diarrhea, and constipation — highest during dose escalation, diminishing over time. In Phase 2, retatrutide's gastrointestinal side effects were described as similar in character and frequency to tirzepatide.
The addition of glucagon receptor activity in retatrutide doesn't appear to produce dramatically different side effects in Phase 2 data. Whether longer-term exposure reveals any glucagon-specific effects is part of what Phase 3 is evaluating.
Tirzepatide (Zepbound) is available now through telehealth providers in most states.
Get My Match →Cost and Access: A Significant Practical Gap
Tirzepatide (Zepbound) has a list price of approximately $1,060/month. With manufacturer coupons and telehealth access, many patients pay substantially less — and access is available across most US states through licensed telehealth platforms.
Retatrutide pricing has not been set. Based on Eli Lilly's pricing history, expect it to be in the same tier as tirzepatide. More importantly: it's not available at any price until FDA approval, which won't happen before 2027.
Who Should Consider Each
For a patient making a treatment decision today: Tirzepatide. It's approved, accessible, has Phase 3 efficacy data, and produces clinically significant weight loss. Waiting 2+ years for retatrutide means 2+ years without treatment — during which substantial metabolic benefit is available.
For a patient already on tirzepatide who isn't responding adequately: Discuss options with your provider now. Retatrutide may eventually offer a path, but it's not available. Other options — dose adjustment, augmentation strategies, reassessment of contributing factors — are available today.
For a patient who wants to understand the trajectory of obesity medicine: Retatrutide represents where the field is moving. Triple agonism, if it holds up in Phase 3, suggests a meaningful ceiling increase in pharmacological weight loss. But the operative word is "if."
See the full retatrutide analysis, all future GLP-1 medications, or the complete comparison hub.
Frequently Asked Questions
Is retatrutide more effective than tirzepatide?
Phase 2 data suggests retatrutide produces greater average weight loss (~24% vs ~20-22%), but these results come from different trials with different populations. A direct head-to-head comparison has not been published. Phase 3 data from the TRIUMPH program will be more definitive.
When will retatrutide be available compared to tirzepatide?
Tirzepatide (Zepbound) is FDA-approved and available now. Retatrutide is in Phase 3 trials with earliest approval expected 2027. That's at minimum a 2-year gap.
Should I wait for retatrutide instead of starting tirzepatide?
For most people, no. Two years of treatment with tirzepatide — which produces 20-22% average weight loss — represents substantial health benefit you'd miss by waiting. Switching medications later is possible if retatrutide receives approval and becomes accessible.
What is the main difference between retatrutide and tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds a third: glucagon. The glucagon component is believed to increase resting metabolic rate and promote fat breakdown, which may explain the additional weight loss seen in Phase 2.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state — matched to your budget. Free. No obligation.
Get My Match — Free →